Antisense paves way for IND for MS drug
Antisense Therapeutics (ASX:ANP) has received a positive response from the US FDA regarding its intention to conduct phase IIb trials of drug candidate ATL1102 in multiple sclerosis (MS).
The company filed a notice that it plans to initiate longer-term human trials as part of an Investigational New Drug application with the US FDA.
The agency has provided Antisense with supportive guidance in the form of a pre-IND assessment of the company’s development strategy for the drug.
Antisense CEO Mark Diamond said the FDA’s response is “an important step in moving ATL1102 forward into late-stage clinical development [and therefore capitalising] on the substantial development and investment made to date on this key project asset”.
He said Antisense is on the search for a pharmaceutical partner to help drive ATL1102’s further development.
Last month, Antisense launched an up to $2.5 million capital raising to help fund the FDA interactions regarding the upcoming trial, as well as partnership efforts for another candidate - ATL1103 - in growth disorder acromegaly.
The company also recently revealed that the phase IIa trial of ATL1102 met its primary end point of a statistically significant reduction in the cumulative number of new active brain lesions in patients taking ATL1102 compared to a placebo.
Antisense Therapeutics (ASX:ANP) shares were trading unchanged at $0.105 as of around 2 pm on Tuesday.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
